Target intelligence / Profile preview

Solute carrier family 6 member 19 (SLC6A19)

Target
SLC6A19
Molecular classification
Transporter, Solute carrier
01

Overview

Solute carrier family 6 member 19 (SLC6A19), also known as broad neutral amino acid transporter 1 (B0AT1), is a sodium-dependent, chloride-independent symporter primarily expressed in the apical membrane of renal proximal tubules and intestinal epithelial cells. It plays a critical role in the absorption and reabsorption of neutral amino acids, including phenylalanine, tryptophan, and branched-chain amino acids. For its proper trafficking and functional expression, SLC6A19 requires association with accessory proteins, specifically angiotensin-converting enzyme 2 (ACE2) in the intestine and collectrin (CLTRN) in the kidney. Loss-of-function mutations in the SLC6A19 gene cause Hartnup disorder, a rare autosomal recessive condition characterized by neutral aminoaciduria, pellagra-like skin rashes, and cerebellar ataxia, though many individuals remain asymptomatic.

In therapeutic development, SLC6A19 has emerged as a highly promising target for metabolic and renal diseases. Inhibiting SLC6A19 prevents the reabsorption of phenylalanine in the kidneys, promoting its excretion in urine and thereby lowering toxic systemic levels in patients with phenylketonuria (PKU). Additionally, SLC6A19 inhibition has shown potential in treating type 2 diabetes, obesity, and chronic kidney disease (CKD) by modulating systemic amino acid levels, improving glucose tolerance, and reducing renal transport burden. Novel small-molecule inhibitors, such as repinatrabit (JNT-517) and MZE-782, target allosteric sites on the transporter to lock it in an inactive conformation, and are currently undergoing clinical evaluation.

Other names
B0AT1Sodium-dependent neutral amino acid transporter B(0)AT1System B(0) neutral amino acid transporter AT1Broad neutral amino acid transporter 1HND
02

Mechanism of action

Allosteric inhibition of the transporter to block the reabsorption and absorption of neutral amino acids, particularly phenylalanine

03

Biological functions

Amino acid transportSodium-dependent symportNutrient absorptionRenal reabsorption
04

Disease associations

PhenylketonuriaHartnup disorderChronic kidney diseaseType 2 diabetesNon-alcoholic steatohepatitisUrea cycle disorder
05

Safety considerations

Hartnup-like symptoms (pellagra, cerebellar ataxia, photosensitive rash) under severe protein malnutritionImpaired absorption of essential amino acidsPotential disruption of ACE2-mediated physiological pathways
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Urinary phenylalaninePlasma phenylalanineUrinary neutral amino acids

Beyond the preview

Go deeper on Solute carrier family 6 member 19 (SLC6A19).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 6 member 19 (SLC6A19).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call